MDGL
MDGL348.730USD
+3.760+1.09%
Close 07/17, 16:00（ET）Quotes delayed by 15 min
7.74BMarket Cap
--P/E TTM
More Details of Madrigal Pharmaceuticals Inc Company
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Company Info
Ticker SymbolMDGL
Company nameMadrigal Pharmaceuticals Inc
IPO dateFeb 06, 2007
Founded at2000
CEOMr. Bill Sibold
Number of employees528
Security typeOrdinary Share
Fiscal year-endFeb 06
Address200 Barr Harbor Dr Ste 400
CityWEST CONSHOHOCKEN
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code19428-2978
Phone14043809263
Websitehttps://www.madrigalpharma.com/
Ticker SymbolMDGL
IPO dateFeb 06, 2007
Founded at2000
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Rebecca A. Taub, M.D.
Dr. Rebecca A. Taub, M.D.
Director
Director
442.32K
-4.06%
Dr. Paul A. Friedman, M.D.
Dr. Paul A. Friedman, M.D.
Director
Director
165.12K
+0.43%
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
11.38K
+6.70%
Dr. David Soergel, M.D.
Dr. David Soergel, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
7.54K
--
Mr. Raymond Cheong, M.D., Ph.D.
Mr. Raymond Cheong, M.D., Ph.D.
Independent Director
Independent Director
2.40K
--
Mr. Kenneth M. (Ken) Bate
Mr. Kenneth M. (Ken) Bate
Independent Director
Independent Director
1.91K
+59.68%
Ms. Shannon Kelley
Ms. Shannon Kelley
Executive Vice President, Chief Legal Counsel
Executive Vice President, Chief Legal Counsel
--
-100.00%
Mr. James M. Daly
Mr. James M. Daly
Independent Director
Independent Director
--
--
Dr. Jacqualyn (Jackie) Fouse, Ph.D.
Dr. Jacqualyn (Jackie) Fouse, Ph.D.
Independent Director
Independent Director
--
--
Mr. Julian C. Baker
Mr. Julian C. Baker
Independent Chairman of the Board
Independent Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Rebecca A. Taub, M.D.
Dr. Rebecca A. Taub, M.D.
Director
Director
442.32K
-4.06%
Dr. Paul A. Friedman, M.D.
Dr. Paul A. Friedman, M.D.
Director
Director
165.12K
+0.43%
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
11.38K
+6.70%
Dr. David Soergel, M.D.
Dr. David Soergel, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
7.54K
--
Mr. Raymond Cheong, M.D., Ph.D.
Mr. Raymond Cheong, M.D., Ph.D.
Independent Director
Independent Director
2.40K
--
Mr. Kenneth M. (Ken) Bate
Mr. Kenneth M. (Ken) Bate
Independent Director
Independent Director
1.91K
+59.68%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Thu, Jun 19
Updated: Thu, Jun 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Janus Henderson Investors
9.93%
Paulson & Co. Inc.
9.46%
Avoro Capital Advisors LLC
9.11%
RTW Investments L.P.
8.98%
Baker Bros. Advisors LP
8.91%
Other
53.62%
Shareholders
Shareholders
Proportion
Janus Henderson Investors
9.93%
Paulson & Co. Inc.
9.46%
Avoro Capital Advisors LLC
9.11%
RTW Investments L.P.
8.98%
Baker Bros. Advisors LP
8.91%
Other
53.62%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
51.07%
Investment Advisor
24.99%
Hedge Fund
17.33%
Family Office
9.46%
Individual Investor
4.80%
Research Firm
3.00%
Corporation
2.95%
Pension Fund
0.54%
Sovereign Wealth Fund
0.52%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
643
23.61M
106.34%
-1.53M
2025Q1
668
23.83M
107.57%
-1.54M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Janus Henderson Investors
2.21M
9.93%
-2.54K
-0.12%
Mar 31, 2025
Paulson & Co. Inc.
2.10M
9.46%
+57.52K
+2.82%
Mar 31, 2025
Avoro Capital Advisors LLC
2.02M
9.11%
-6.78K
-0.33%
Mar 31, 2025
RTW Investments L.P.
1.99M
8.98%
--
--
Mar 31, 2025
Baker Bros. Advisors LP
1.98M
8.91%
+2.86K
+0.14%
Jun 20, 2025
The Vanguard Group, Inc.
1.69M
7.6%
-16.02K
-0.94%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.32M
5.92%
-17.10K
-1.28%
Mar 31, 2025
State Street Global Advisors (US)
758.51K
3.42%
-22.78K
-2.92%
Mar 31, 2025
SQN, L.L.C.
655.54K
2.95%
--
--
Apr 01, 2025
Fidelity Management & Research Company LLC
551.75K
2.48%
-197.85K
-26.39%
Mar 31, 2025
View more
Related ETFs
Updated: Sun, Jul 6
Updated: Sun, Jul 6
Name
Proportion
Invesco Dorsey Wright Healthcare Momentum ETF
2.95%
Virtus LifeSci Biotech Products ETF
2.02%
SPDR S&P Biotech ETF
1.95%
Direxion Daily S&P Biotech Bull 3X Shares
1.2%
Global X Guru Index ETF
1.17%
Tema Heart & Health ETF
0.93%
ProShares Ultra Nasdaq Biotechnology
0.77%
Invesco Nasdaq Biotechnology ETF
0.68%
First Trust Innovation Leaders ETF
0.61%
iShares Biotechnology ETF
0.54%
View more
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion2.95%
Virtus LifeSci Biotech Products ETF
Proportion2.02%
SPDR S&P Biotech ETF
Proportion1.95%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion1.2%
Global X Guru Index ETF
Proportion1.17%
Tema Heart & Health ETF
Proportion0.93%
ProShares Ultra Nasdaq Biotechnology
Proportion0.77%
Invesco Nasdaq Biotechnology ETF
Proportion0.68%
First Trust Innovation Leaders ETF
Proportion0.61%
iShares Biotechnology ETF
Proportion0.54%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
